Stephen Ferrone, CEO of Biotech Marketing Firm Immunosyn, to Present at the National Investment Banking Association (NIBA) Conference in Las Vegas
"It is important that we increase market awareness of ImmunosynCorporation, our vision and the steps which have been taken, moving us closerto achieving our goals," says Stephen D. Ferrone, CEO and President ofImmunosyn. "We are therefore privileged to present our company to the elitegroup of broker/dealers, investment bankers and institutional investors at theNIBA conference."
Immunosyn's company objectives, overview and product information will becommunicated to target audiences at select conferences such as NIBA.Presentations will be made which include market data, research information andmilestones achieved. As part of Immunosyn's presentation at NIBA, Mr. Ferronewill focus on the biopharmaceutical SF-1019, including information aboutregulatory approvals and results of a recent study.
A video version of the Immunosyn presentation that is being shared withinstitutional investors at the NIBA Conference will be launched on thecompany's News / Media page at http://www.immunosyn.com on Friday,November 30, 2007, 9:00 AM EST.
About the National Investment Banking Association
The National Investment Banking Association is a national tradeassociation of regional and independent brokerages, investment banking firms,and related capital market service providers. NIBA member firms havesuccessfully completed some 850+ equity offerings totaling approximately $9.5billion in new capital for America's finest emerging growth companies.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans tomarket and distribute life enhancing therapeutics. Currently, the company hasexclusive worldwide rights from its largest shareholder, ArgyllBiotechnologies, LLC, to market, sell and distribute SF-1019, a compound thatwas developed from extensive research into Biological Response Modifiers(BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatoryapproval of SF-1019 in several countries and preparations for clinical trialsare underway in both the US and Europe. Research suggests that SF-1019 hasthe potential to affect a number of clinical conditions includingcomplications from Diabetic Mellitus such as Diabetic Neuropathy (DN) anddiabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS)and neurological disorders such as Chronic Inflammatory DemyelinatingPolyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).(For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com)
The above news release contains forward-looking statements. Thesestatements are based on assumptions that management believes are reasonablebased on currently available information, and include statements regarding theintent, belief or current expectations of the Company and its management.Prospective investors are cautioned that any such forward-looking statementsare not guarantees of future performance, and are subject to a wide range ofbusiness risks, external factors and uncertainties. Actual results may differmaterially from those indicated by such forward-looking statements. Foradditional information, please consult the Company's most recent publicfilings and Annual Report on Form 10-K for its most recent fiscal year. TheCompany assumes no obligation to update the information contained in thispress release, whether as a result of new information, future events orotherwise.
SOURCE Immunosyn Corporation
You May Also Like